#### Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 3

#### LABORATORY CORP OF AMERICA HOLDINGS

Form 3

February 25, 2015

## FORM 3

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB

3235-0104

\_\_\_\_\_

Number: January 31,

Estimated average

**OMB APPROVAL** 

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

burden hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person \* Statement LABORATORY CORP OF AMERICA HOLDINGS HERRING JOSEPH L (Month/Day/Year) [LH] 02/19/2015 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 210 CARNEGIE CENTER (Check all applicable) (Street) 6. Individual or Joint/Group Filing(Check Applicable Line) Director 10% Owner \_X\_ Form filed by One Reporting \_X\_\_ Officer Other Person PRINCETON. NJÂ 08540 (give title below) (specify below) \_ Form filed by More than One CEO of Covance Drug Division Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security 2. Amount of Securities 3. 4. Nature of Indirect Beneficial (Instr. 4) Beneficially Owned Ownership Ownership (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) Common Stock D Â 36,859 Common Stock By Trustee (1) 4,508 Ι Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

required to respond unless the form displays a

currently valid OMB control number.

(Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
			Derivative	Security:	

#### Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 3

Date Expiration Title Amount or Security Direct (D)

Exercisable Date Number of Shares (I)

(Instr. 5)

## **Reporting Owners**

Reporting Owner Name / Address	Kelationships				
	Director	10% Owner	Officer	Other	
HERRING JOSEPH L 210 CARNEGIE CENTER PRINCETON, NJ 08540	Â	Â	CEO of Covance Drug Division	Â	

# **Signatures**

/s/ F. Samuel Eberts III, Attorney-in-Fact for Joseph Herring 02/25/2015

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares held in a 401(k) plan. The shares were liquidated by the Trustee of the Plan in a non-discretionary transaction on February 23, 2015.

Â

#### **Remarks:**

Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2